Real-World Analysis of the Pharmaco-Utilization of Intravitreal Vascular Endothelial Growth Factor (VEGF) Inhibitors and Healthcare Costs Among Patients with WET Age-Related Macular Degeneration (WAMD) in Italy

Author(s)

Perrone V1, Giacomini E1, Alessandrini D1, Ritrovato D2, Veronesi C1, Degli Esposti L1
1CliCon S.r.l. Health, Economics & Outcomes Research, Ravenna, Italy, 2Novartis Farma Italy, Origgio, Italy

OBJECTIVES. To analyse the pharmaco-utilization of VEGF inhibitors and healthcare costs among wAMD-patients in Italian real-world settings.

METHODS. This retrospective observational analysis was based on administrative databases of 2 regions and 3 Local Health Units in Italy, accounting approximately 6million health-assisted individuals. Patients were included during January/2010—December/2017, if they were ≥50 years old and presented a prescription for VEGF inhibitors (aflibercept/pegaptanib/ranibizumab) and/or i)discharge diagnosis (ICD-9-CM-code=362.52) for wAMD or ii)injections of vitreous substitute (procedural/specialistic code=14.75). Patients with injections of vitreous substitute presenting diabetes diagnosis, dexamethasone intravitreal implant or diagnosis for other ophthalmic pathologies with indications for intravitreal treatments were excluded. Patients were followed-up from index-date (corresponding to the first match with inclusion criteria) to December 2018. Pharmaco-utilization and cost analyses were performed only on alive patients prescribed VEGF inhibitors.

RESULTS. Preliminary results showed that 1,287 wAMD-patients were included (51.6% male). Mean age±SD was 73.4±9.8. Patients’ distribution by age decades was: 10.7% in 50-59 age decade, 21.9% in 60-69, 38.2% in 70-79,29.2% ≥80 years old. Mean follow-up length was 4.0±2.1 years; during this time, 153 (11.9%) patients died. VEGF inhibitors were prescribed to 795 patients: 204 (25.7%) aflibercept, 14 (1.8%) pegaptanib, 577 (72.6%) ranibizumab. Mean number of VEGF inhibitor prescriptions decreased during follow-up: 3.6±2.0 (4.0±1.9 aflibercept, 3.6±2.1 pegaptanib, 3.4±2.0 ranibizumab) during 1styear, 1.1±1.9 (0.9±1.5 aflibercept, 0.4±0.9 pegaptanib, 1.2±2.0 ranibizumab) for 2ndyear and 0.9±1.8 (0.1±0.5 aflibercept, none pegaptanib, 1.0±1.9 ranibizumab) for 3rdyear. During 1styear of follow-up, mean healthcare costs were €6,075.88 for aflibercept-users, €7,737.70 for pegaptanib-users and €5,894.80 for ranibizumab-users. 72.3% of treatment costs per patient prescribed VEGF inhibitor was related to VEGF inhibitor therapies. Treatment costs were €3,545.09(aflibercept-users), €3,212.92(pegaptanib-users), €3,446.13(ranibizumab-users).

CONCLUSIONS. VEGF inhibitors prescriptions were observed to decrease over time, suggesting a trend of under-treatment among wAMD-patients analysed that could ultimately lead to the worsening of clinical outcomes and higher consumption of healthcare resources.

Conference/Value in Health Info

2020-11, ISPOR Europe 2020, Milan, Italy

Value in Health, Volume 23, Issue S2 (December 2020)

Code

PSS7

Topic

Economic Evaluation

Disease

Sensory System Disorders

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×